Member Directory - TB Working Group

Susan Swindells is a Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA.  A native of England, Dr. Swindells earned her medical degree from University College London in 1977, with postgraduate training in England and at the University of Washington in Seattle.  She has been involved in HIV care since 1984. 

Nicole Ammerman is a Research Associate in the Department of Medicine, Division of Infectious Diseases, at the Johns Hopkins University School of Medicine. She has a PhD in Microbiology and Immunology from the University of Maryland School of Medicine and an ScM in Epidemiology from the Johns Hopkins University Bloomberg School of Public Health. Her research focuses on the experimental chemotherapy of tuberculosis and nontuberculous mycobacterial diseases.

Stephanie E. Barrett, PhD., is a Principal Scientist at Merck & Co., Inc. in the Department of Biopharmaceutics and Specialty Dosage Forms.

Richard E. Chaisson, MD, is Professor of Medicine, Epidemiology, and International Health at Johns Hopkins University and Director of the Johns Hopkins Center for TB Research and the Center for AIDS Research.

Tine has a PhD in Veterinary Sciences from the University of Ghent, Belgium and earned her MBA in Pharmaceutical Management from Drexel LeBow College of Business. She has additional Masters degrees in Biology and Teaching. Tine is Compound Development Team Lead for Tuberculosis at Johnson & Johnson Global Public Health.

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). He is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences in the Johns Hopkins University School of Medicine.  He is also Professor of International Health in the Johns Hopkins University Bloomberg School of Public Health. 

Jay Grobler is Director, Infectious Disease Biology, at Merck Research Laboratories.

Daria Hazuda, PhD, trained as a biochemist at the State University of New York at Stony Brook, N.Y. After completing her postdoctoral research fellowship in the department of Immunology at Smith Kline, she joined the antiviral research group as a Senior Research Biochemist at Merck in 1989.

Richard Hoetelmans, PharmD, PhD, trained as a pharmacist at Utrecht University, Netherlands. After completing his PhD in Amsterdam on the topic of antiretroviral drugs, he joined Tibotec’s Clinical Pharmacology department in 2001, and is currently the Therapeutic Area Leader for Quantitative Sciences and Group Lead for Global Clinical Pharmacology for Janssen’s Infectious Diseases & Vaccines, and Global Public Health franchises, based in Beerse, Belgium.

Dr. Nuermberger is an Associate Professor of Medicine and International Health at Johns Hopkins University. His primary research interest is the experimental chemotherapy of TB. The work uses well-validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new antimicrobials.

David has >20 years of infectious disease drug discovery experience with a focus on HIV-1 and HCV. In 2011 he was given the responsibility of directing Merck’s Neglected Tropical Disease discovery efforts that includes tuberculosis, macrofilaria, Chagas, Leishmania, malaria and Ebola.

Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. He is also affiliated to the MRC Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine. He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, and a member of the steering committee for the Academy of Pharmaceutical Sciences Nanomedicines Focus Group. 

Dr. Chuck Peloquin received his BS in Pharmacy from the University of Connecticut and his Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. 

Dr. Podany is currently an Assistant Professor in the department of pharmacy practice at the University of Nebraska Medical Center.

Dr. Rangaka is an Associate Professor within the Institute of Global Health, University College London (UCL), United Kingdom. She is also affiliated to the MRC Clinical Trials Unit at UCL and is an honorary Associate Professor at the University of Cape Town (UCT), South Africa.

Bart Remmerie, Chem. Eng., graduated as a bio-engineer and as environmental engineer at Ghent University, Belgium. He started at Janssen (Bioanalysis) in 1994 and joined the Clinical Pharmacology group in 2006, initially primarily working on neuroscience projects, and more recently also on anti-infectives. 

Kimberly Scarsi is an Associate Professor at the University of Nebraska Medical Center’s (UNMC) College of Pharmacy. Her research program focuses on optimizing pharmacologic therapies for persons living with HIV, with an emphasis on tuberculosis and gender related issues. 

Dr Marco Siccardi graduated with an MSc in Clinical Biology (2006) at the University of Turin, Italy. He obtained his PhD at the University of Liverpool, Liverpool, UK (2011) focusing his research on molecular mechanisms influencing drug distribution and predictors of exposure in patients. He was recently appointed as a Lecturer in Pharmacology across the faculties of Health & Life Sciences and Science & Engineering at the University of Liverpool.